Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsASX:RAD -11.11% Days Payable is 437.44 as of Jun. 2025, which is 42% below its 10-year median of 754.85. The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, Radiopharm Theranostics ranks better than 82.04% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAD vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Radiopharm Theranostics's Days Payable for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (ASX:RAD) has a Days Payable of 437.44 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radiopharm Theranostics and its competitors. This is 42% below median its historical median of 754.85. Over the past decade, Radiopharm Theranostics' Days Payable has ranged from 599.85 to 860.63. According to the industry distribution chart, Radiopharm Theranostics ranks #127 out of 707 companies in the Biotechnology industry, placing it in the top 18%.
Is Radiopharm Theranostics' Days Payable too high?
Radiopharm Theranostics' current Days Payable of 437.44 is 42% below median its 10-year median of 754.85. Over the past 10 years, this metric has ranged from a low of 599.85 to a high of 860.63. The Biotechnology industry median Days Payable is 111.24. Radiopharm Theranostics' value of 437.44 is 293.2% above this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #127 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Radiopharm Theranostics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #127 out of 707 companies for Days Payable. This places Radiopharm Theranostics in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.24. Radiopharm Theranostics' value of 437.44 is 293.2% above this benchmark. Historically, Radiopharm Theranostics' own Days Payable has ranged from 599.85 to 860.63 over the past decade. While the company's 10-year median is 754.85 vs. the industry median of 111.24, Radiopharm Theranostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Days Payable of 437.44 is 293.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Days Payable is 437.44, which is 42% below median its own 10-year median of 754.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (ASX:RAD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% below its estimated fair value. The current Days Payable is 437.44, which is 42% below median its 10-year median of 754.85 and 293.2% above the Biotechnology industry median of 111.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Days Payable is 437.44 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAD has been successfully added to your 
